{"gene":"ELF3","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1997,"finding":"ELF3 (ESE-1) was identified as an epithelium-specific ETS transcription factor containing two DNA-binding domains: an ETS domain and an A/T hook domain (found in HMG proteins). It binds with high affinity to ETS binding sites in the SPRR2A promoter and transactivates SPRR2A and the Endo A gene enhancer, establishing it as a transcriptional activator of keratinocyte differentiation target genes.","method":"Molecular cloning, electrophoretic mobility shift assay (EMSA), transient transfection/luciferase reporter assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — original characterization with multiple orthogonal methods (EMSA, reporter assay, expression profiling), replicated across subsequent studies","pmids":["9234700"],"is_preprint":false},{"year":1998,"finding":"ELF3 (ERT) activates transcription of the TGF-β type II receptor (RII) gene by binding to ETS binding sites in the TGF-β RII promoter (response element at +13 to +24 and multiple sites between -1816 and -82). Deletion mapping showed the transactivation domain resides in the amino terminus and the DNA-binding domain in the carboxyl-terminal region.","method":"Yeast one-hybrid screening, luciferase reporter assay, EMSA, deletion mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (yeast one-hybrid, EMSA, reporter assay, domain mapping) in a single study, replicated by subsequent work","pmids":["9417054"],"is_preprint":false},{"year":1999,"finding":"The human ELF3 gene contains nine exons spanning ~5.8 kb. A 1.5-kb fragment of the 5' upstream region acts as a functional promoter in epithelial cell lines, containing TATA and CCAAT boxes and potential binding sites for Ets factors and NF-κB.","method":"Genomic cloning, transfection experiments with promoter-reporter constructs","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter characterization by transfection, single lab, two methods","pmids":["10049594"],"is_preprint":false},{"year":2000,"finding":"ELF3 (ERT) overexpression in Hs578t breast cancer cells induces endogenous TGF-β type II receptor mRNA and protein expression, restores TGF-β growth inhibitory signaling (~50% growth reduction with exogenous TGF-β1), and reduces tumorigenicity in athymic mice, confirming ELF3 as a transcriptional activator of TGF-β RII in vivo.","method":"Retroviral overexpression, Northern blot, luciferase reporter assay, xenograft mouse model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional rescue in cell lines and in vivo xenograft, multiple orthogonal methods, consistent with in vitro mechanistic data from prior study","pmids":["10644990"],"is_preprint":false},{"year":2000,"finding":"ELF3 (ESE-1) is expressed in corneal epithelial cells and is upregulated during differentiation. It transactivates the regulatory element of cornea-specific K12 keratin. Introduction of ESE-1 antisense RNA in immortalized human corneal epithelial cells impairs their differentiation.","method":"Northern blot, luciferase reporter assay, antisense RNA loss-of-function","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus antisense loss-of-function with differentiation phenotype, single lab","pmids":["11025204"],"is_preprint":false},{"year":2001,"finding":"Loss of ELF3 (ERT) expression in gastric cancer cell lines with undetectable TGF-β RII mRNA is linked to inactivation of a sequence-specific DNA binding protein (nuclear protein complex) that recognizes the ERT promoter element ESE (-186 to -177), suggesting that loss of this transcriptional activator contributes to silencing of ERT and subsequent TGF-β resistance.","method":"Promoter cloning, EMSA, transient transfection, deletion analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — EMSA and reporter assay, single lab, mechanism partially defined","pmids":["11313868"],"is_preprint":false},{"year":2003,"finding":"Induction of ELF3 (ESE-1) gene expression by IL-1β in synovial fibroblasts, chondrocytes, osteoblasts, and monocytes requires activation of NF-κB and binding of p50 and p65 NF-κB family members to a high-affinity NF-κB binding site in the ESE-1 promoter. Overexpression of IκB using adenoviral vector blocked IL-1β-induced ESE-1 mRNA expression. ChIP confirmed NF-κB binds the ESE-1 promoter in vivo.","method":"Luciferase reporter assay with promoter mutants, EMSA with supershift assay, adenoviral IκB overexpression, chromatin immunoprecipitation (ChIP)","journal":"Arthritis and rheumatism","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (reporter assay, EMSA, ChIP, adenoviral KD), functionally confirmed in primary cells","pmids":["12746898"],"is_preprint":false},{"year":2003,"finding":"ELF3 (ESE-1/Ese-1) cooperates functionally with the Skn-1a isoform of Oct-11 to drive SPRR2A expression in keratinocyte terminal differentiation. This cooperativity depends on an N-terminal pointed-like domain in Skn-1a; the Skn-1d1 isoform counteracts this cooperativity. Identifies ELF3 as part of a multi-factor complex regulating keratinocyte differentiation.","method":"Transient co-transfection reporter assays, domain deletion analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cooperativity in reporter assays with domain mapping, single lab","pmids":["12624109"],"is_preprint":false},{"year":2004,"finding":"ELF3 (ESE-1) protein is cytoplasmic in human breast cancer cells. Stably expressed GFP-ESE-1 transforms MCF-12A human mammary epithelial cells via a cytoplasmic, non-transcriptional mechanism mediated by the unique 40-amino acid serine/aspartic acid-rich (SAR) domain. Nuclear localization of ESE-1 induces apoptosis via a transcription-dependent mechanism. Fusion of an NLS to ESE-1 or SAR domain inhibits transforming capacity.","method":"Stable transfection, GFP subcellular localization, NLS/NES fusion constructs, apoptosis assays, domain deletion analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (stable transfection, domain mapping, NLS/NES manipulation, apoptosis readout), defines two distinct mechanistic functions by subcellular compartment","pmids":["15169914"],"is_preprint":false},{"year":2004,"finding":"ELF3 (ESE-1) is a novel transcriptional mediator of angiopoietin-1 (Ang-1) expression in the setting of inflammation. ESE-1 binds to specific ETS sites within the Ang-1 promoter that are required for transactivation; mutation of a high-affinity ESE-1 binding site markedly reduces Ang-1 transactivation and cytokine inducibility. Transcriptional profiling confirmed direct induction of endogenous Ang-1 by ESE-1.","method":"Transient transfection reporter assay, site-directed mutagenesis of promoter, EMSA, transcriptional profiling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis of binding sites, EMSA, and transcriptional profiling with multiple orthogonal methods in single study","pmids":["14715662"],"is_preprint":false},{"year":2005,"finding":"ELF3 (ESE-1) binds to multiple ETS sites on the COX-2 promoter and activates COX-2 expression in response to LPS and pro-inflammatory cytokines in monocytes/macrophages. Mutation of ETS sites in the COX-2 promoter or overexpression of dominant-negative ESE-1 inhibits LPS-mediated COX-2 induction. ESE-1's effect is enhanced by cooperation with NF-κB and NFAT.","method":"Luciferase reporter assay, promoter mutagenesis, EMSA, dominant-negative overexpression, co-transfection","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — promoter mutagenesis, dominant-negative, EMSA, multiple orthogonal methods, single lab but thorough mechanistic dissection","pmids":["15794755"],"is_preprint":false},{"year":2008,"finding":"ELF3 (ESE-1) expression in airway epithelial cells is upregulated by IL-1β and TNF-α via NF-κB activation. ESE-1 also upregulates ESE-3 expression and downregulates its own induction by cytokines (negative autoregulation). In Elf3 knockout mice, IL-6 expression is downregulated following inflammatory stimulation.","method":"NF-κB promoter analysis, transfection, siRNA, Elf3 knockout mouse","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 / Strong — promoter characterization, KO mouse with defined cytokine phenotype, in vitro and in vivo methods, replicated NF-κB mechanism","pmids":["18475289"],"is_preprint":false},{"year":2008,"finding":"ELF3 (ESE-1) is a potent transcriptional repressor of the type II collagen gene (COL2A1) in chondrocytes in response to IL-1β, via NF-κB-dependent binding to tandem ETS sites at -403/-381 bp in the COL2A1 promoter. ChIP confirmed IL-1β-induced ESE-1 binding to the COL2A1 promoter in vivo. ETS-1, by contrast, activates COL2A1 and blocks IL-1β inhibition.","method":"Transient co-transfection, siRNA, ChIP, EMSA, promoter deletion analysis","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP, EMSA, siRNA, reporter with deletion mapping, multiple orthogonal methods","pmids":["18044710"],"is_preprint":false},{"year":2008,"finding":"ELF3 (ESE-1) mediates tolfenamic acid-induced EGR-1 expression and apoptosis in colorectal cancer cells. ESE-1 binds to an ETS binding site at -400/-394 bp in the EGR-1 promoter (confirmed by EMSA and ChIP), and tolfenamic acid promotes nuclear translocation of ESE-1. Silencing ESE-1 attenuates tolfenamic acid-induced EGR-1 expression and apoptosis.","method":"EMSA, ChIP, luciferase reporter assay, siRNA knockdown, nuclear translocation assay","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — EMSA, ChIP, siRNA, reporter assay, and localization experiment in a single mechanistically thorough study","pmids":["19074849"],"is_preprint":false},{"year":2008,"finding":"ELF3 (ESE-1) suppresses invasion of oral squamous cell carcinoma cells by transcriptionally repressing MMP-9 via an ETS binding site in the MMP-9 promoter. ESE-1 transfection reduces invasion activity and 92 kDa gelatinolytic activity, and luciferase/mutation analysis confirmed that the ETS binding site in the MMP-9 promoter mediates this suppression.","method":"Transfection, invasion assay, gelatin zymography, Northern blot, luciferase assay, mutation analysis","journal":"Oral diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional invasion assay, luciferase/mutation analysis, single lab with multiple methods","pmids":["18302674"],"is_preprint":false},{"year":2010,"finding":"ELF3 (ESE-1) plays a counter-regulatory role in angiotensin II (Ang II)-mediated vascular inflammation and remodeling. ESE-1 KO mice show exaggerated intimal medial thickness, perivascular fibrosis, T cell and macrophage infiltration, greater PCNA staining, blunted NOS2 (iNOS) induction, and an exaggerated systolic blood pressure response to Ang II compared to wild-type controls.","method":"ESE-1 knockout mice, Ang II infusion model, histology, immunostaining","journal":"American journal of hypertension","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with defined vascular phenotype, single lab, multiple histological readouts but no in vitro mechanistic dissection","pmids":["20689519"],"is_preprint":false},{"year":2011,"finding":"Elf3 regulates allergic airway inflammation by controlling dendritic cell (DC)-driven T cell differentiation. Elf3−/− mice show impaired IL-6 and IL-12 production by DCs, impaired Th1 and Th17 differentiation, and exaggerated Th2 responses with increased IgE. The impairment of IL-12 production was attributed to impaired IL-12p40 gene induction in Elf3-deficient DCs.","method":"Elf3 knockout mice, OVA sensitization/challenge models, ELISA, flow cytometry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse with multiple defined cellular and molecular phenotypes, in vivo and ex vivo methods, identifies IL-12p40 as a specific downstream target","pmids":["21948981"],"is_preprint":false},{"year":2011,"finding":"ESE-1 (ELF3) SAR domain-mediated mammary cell transformation occurs exclusively in the cytoplasm. NLS mapped to six basic amino acids (242HGKRRR247) in the AT-hook domain. Two CRM1-dependent NES motifs were identified: NES1 in the pointed domain (102LCNCALEELRL112) and NES2 in the DNA binding domain (275LWEFIRDILI284). Site-specific mutation of NES2 abrogates transforming activity. The SAR domain is accessible for protein-protein interactions.","method":"GFP reporter subcellular localization, site-directed mutagenesis, NLS/NES fusion constructs, transformation assay","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — systematic domain mapping with site-directed mutagenesis and GFP localization reporters, multiple constructs and functional readouts","pmids":["21871131"],"is_preprint":false},{"year":2013,"finding":"ELF3 is a repressor of androgen receptor (AR) transcriptional activity in prostate cancer cells. ELF3 physically interacts with AR (biochemical pulldown), and this interaction inhibits recruitment of AR to androgen response elements within target gene promoters. ELF3 knockdown increases AR transcriptional activity and promotes cell migration; ELF3 overexpression inhibits tumor growth in vitro and in xenograft models.","method":"Reporter-based transfection assays, endogenous AR target gene qPCR, siRNA knockdown, co-immunoprecipitation/pulldown, ChIP, xenograft mouse model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — physical interaction demonstrated, ChIP showing impaired AR recruitment, functional rescue/KD with xenograft validation, multiple orthogonal methods","pmids":["23435425"],"is_preprint":false},{"year":2016,"finding":"RIPK4 is upstream of ELF3 in keratinocytes: RIPK4 is required for PMA-inducible ELF3 gene expression. RIPK4 acts via phosphorylation and activation of IRF6, and IRF6 in turn regulates ELF3 expression. GRHL3, a downstream target of IRF6, also contributes to ELF3 regulation. ELF3 in this pathway regulates SPRR1A, SPRR1B, and TGM1 expression during keratinocyte cornification.","method":"siRNA knockdown of RIPK4, IRF6, GRHL3; qRT-PCR; Western blot","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis by sequential siRNA knockdown, single lab with multiple targets validated","pmids":["27667567"],"is_preprint":false},{"year":2018,"finding":"ELF3 promotes EMT in hepatocellular carcinoma by transcriptionally repressing miR-141-3p, thereby de-repressing ZEB1. ChIP assays showed ELF3 binds the miR-141-3p promoter to suppress its transcription. ELF3 knockdown reverses EMT via miR-141-3p upregulation and ZEB1 repression.","method":"Gain/loss-of-function studies, ChIP assay, Western blot, migration/invasion assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct promoter binding, functional rescue experiments, single lab","pmids":["29523781"],"is_preprint":false},{"year":2018,"finding":"ELF3 is a negative regulator of EMT transcription factor ZEB1 through its function as an antagonist of Wnt and RAS oncogenic signaling in colorectal cancer cells. ELF3 expression is reduced in response to oncogenic signaling (mutant β-catenin, inducible mutant RAS) and is anti-correlated with ZEB1 and EMT markers.","method":"RNA-Seq, siRNA, Western blot, analysis of colorectal cancer TCGA datasets, tumor/normal protein localization","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — RNA-Seq combined with siRNA functional validation, but pathway epistasis indirect; single lab","pmids":["30148686"],"is_preprint":false},{"year":2019,"finding":"ELF3 is amplified at chromosome 1q32.1 in lung adenocarcinoma (LUAD), and ELF3 expression is required for tumor growth. Gene dosage and promoter hypomethylation affect the locus in up to 80% of LUAD analyzed. Pan-cancer network analysis supports subtype and tissue specificity of ELF3's oncogenic role in LUAD.","method":"Genomic analysis, functional KD in LUAD cells, pan-cancer expression network analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and functional evidence (KD with tumor growth readout), single lab, multiple data types","pmids":["31780666"],"is_preprint":false},{"year":2021,"finding":"ELF3 is required for high-level HLA-C expression on extravillous trophoblasts (EVTs). ELF3 and MED1 bind to the proximal HLA-C promoter region (confirmed by ChIP-PCR). ELF3 creates an autoregulatory positive feedback loop by binding its own promoter. The ELF3 gene is regulated by a superenhancer spanning >5 Mb (identified by ATAC-seq and JQ1 sensitivity). The small molecule wrenchnolol blocks ELF3-MED23 interaction, disrupting the feedback loop and downregulating HLA-C.","method":"ChIP-PCR, siRNA knockdown, ATAC-seq, wrenchnolol treatment, single-cell RNA-seq","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP, siRNA, pharmacological inhibition, ATAC-seq, multiple orthogonal methods defining autoregulation and co-activator interaction","pmids":["33622787"],"is_preprint":false},{"year":2021,"finding":"ELF3 is transcriptionally identified as a direct repressor of lncRNA UBE2CP3 in gastric cancer. ELF3 downregulation (via SNAI2 repression of ELF3) leads to UBE2CP3 upregulation, which promotes cancer progression via a miR-138-5p/ITGA2 ceRNA axis.","method":"ChIP, luciferase reporter assay, transcriptome sequencing, rescue experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct binding to UBE2CP3 regulatory region, functional rescue, single lab","pmids":["34274947"],"is_preprint":false},{"year":2022,"finding":"In esophageal squamous cell carcinoma, ELF3 promotes EMT by binding to the miR-144 promoter to suppress miR-144-3p transcription, thereby de-repressing ZEB1 and ZEB2. The lncRNA LINC00886, acting via SIRT7-mediated H3K18 deacetylation at the ELF3 promoter, suppresses ELF3 expression, placing SIRT7 as an upstream epigenetic writer controlling ELF3.","method":"ChIP (for ELF3 binding to miR-144 promoter and SIRT7/H3K18ac at ELF3 promoter), luciferase reporter, siRNA, Western blot","journal":"Clinical & experimental metastasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP data for ELF3 binding to miR-144 promoter and epigenetic regulation of ELF3 locus, single lab","pmids":["35616822"],"is_preprint":false},{"year":2022,"finding":"ELF3 functions as a transcription factor for IGF1 in epithelial ovarian cancer under hypoxia. ELF3-mediated increase in IGF1 and VEGF secretion promotes endothelial cell proliferation, migration, and tumor angiogenesis. ELF3 silencing under hypoxia significantly attenuated angiogenic activity and tumorigenesis in ex vivo and xenograft models.","method":"siRNA knockdown, IGF1/VEGF ELISA, endothelial cell proliferation/migration assays, ex vivo and xenograft models","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional KD with in vitro and in vivo angiogenesis readouts; ELF3 as IGF1 transcription factor inferred but direct promoter binding confirmation limited in abstract","pmids":["35695065"],"is_preprint":false},{"year":2022,"finding":"ELF3 deficiency in zebrafish disrupts extracellular matrix (ECM) organization and tissue morphogenesis. Elf3 knockdown (morpholino and CRISPR/Cas9) produces short, bent larvae with notochord, craniofacial cartilage, fin, and neural defects, with disorganized ECM in fin and notochord, and dysregulation of genes encoding ECM proteins and matrix metalloproteinases (MMPs).","method":"Morpholino antisense knockdown, CRISPR/Cas9 knockdown, in situ hybridization, histology, gene expression analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent KD methods in zebrafish with specific developmental and molecular phenotypes, single lab","pmids":["36383615"],"is_preprint":false},{"year":2023,"finding":"ELF3 is required for proinflammatory mediator induction by the synergistic action of IL-17A and TNF in synovial fibroblasts. ELF3 expression is induced by the NF-κB co-factor IκBζ (synthesized in response to IL-17A+TNF), and requires NF-κB signaling and C/EBPβ. siRNA depletion of ELF3 attenuates cytokine and MMP induction. Overexpression of ELF3 or IκBζ synergizes with TNF to upregulate CCL8, and ELF3 depletion abrogates CCL8 induction by IκBζ+TNF.","method":"siRNA knockdown, transient overexpression, signaling inhibitors, qRT-PCR, HEK293 and primary synovial fibroblast experiments","journal":"Rheumatology (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (sequential siRNA), overexpression rescue, single lab with multiple cell types","pmids":["35792833"],"is_preprint":false},{"year":2023,"finding":"ELF3 suppresses gallbladder cancer development by directly repressing epiregulin (EREG) transcription, thereby reducing EGFR/mTORC1 signaling. In vivo (KPCE mouse model), loss of Elf3 leads to upregulation of Ereg and EGFR/mTORC1. ChIP of Elf3-overexpressing organoids confirmed direct ELF3 binding to the Ereg locus. CRISPR deletion of Ereg in KPCE organoids normalized EGFR/mTORC1 activity.","method":"Autochthonous mouse model (KPCE), organoids, RNA-seq, ChIP, CRISPR/Cas9 deletion, Western blot, allograft models","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo autochthonous model, organoids, ChIP confirming direct binding, CRISPR epistasis confirming pathway dependence, multiple orthogonal methods","pmids":["37345534"],"is_preprint":false},{"year":2023,"finding":"ELF3 is an oncogenic transcription factor in ASCL1-positive neuroendocrine carcinoma (NEC), regulated by a super-enhancer. Combining CUT&Tag (H3K27ac) and ELF3 knockdown RNA-seq defined the ELF3 transcriptional network, including downstream targets AURKA, CDC25B, CLDN4, ITGB6, and YWHAB. ELF3 depletion leads to poor NEC cell viability.","method":"ATAC-seq, CUT&Tag (H3K27ac), ELF3 siRNA knockdown + RNA-seq, loss-of-function cell viability assay","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ATAC-seq, CUT&Tag, and KD-RNA-seq define transcriptional network, single lab with multiple epigenomic and transcriptomic methods","pmids":["36840413"],"is_preprint":false},{"year":2023,"finding":"Retinoic acid signaling (RAR/RXR) and Elf3 upregulate Netrin-1 in disseminated pancreatic ductal adenocarcinoma tumor cells as part of a feedforward metastatic niche mechanism involving hepatic stellate cell activation and retinoic acid secretion.","method":"In vitro and in vivo metastasis models, gene expression analysis, pathway inhibition","journal":"Cell reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ELF3's direct mechanistic role (e.g., direct promoter binding to Netrin-1) not explicitly demonstrated in abstract; indirect pathway inference only","pmids":["37922311"],"is_preprint":false},{"year":2024,"finding":"ELF3 directly binds to the SLC31A1 (copper transporter) promoter and transcriptionally activates it, as demonstrated by luciferase reporter assay and ChIP. ELF3 is upregulated in cisplatin-induced acute kidney injury and positively correlates with SLC31A1 expression; ELF3-driven SLC31A1 induction increases copper uptake, causing mitochondrial dysfunction and cuproptosis.","method":"Luciferase reporter assay, ChIP, siRNA knockdown, Western blot, in vivo mouse AKI model","journal":"Chemico-biological interactions","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — direct promoter binding by ChIP and reporter assay, functional knockdown with in vivo model, single lab","pmids":["38462020"],"is_preprint":false},{"year":2024,"finding":"WTAP-mediated N6-methyladenosine (m6A) modification of ELF3 mRNA promotes ELF3 expression in an m6A-dependent manner in human dermal fibroblasts. ELF3 overexpression induces cellular senescence; ELF3 directly binds the IRF8 promoter at the -817 to -804 site to induce IRF8-mediated SASP (senescence-associated secretory phenotype). shWTAP suppresses fibroblast senescence, which is reversed by exogenous ELF3 overexpression.","method":"Proteomics, m6A sequencing, ChIP (ELF3 binding to IRF8 promoter), siRNA/shRNA, overexpression, in vivo skin aging model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — ChIP confirming direct ELF3-IRF8 promoter binding, m6A mechanism, rescue experiments; single lab","pmids":["38481803"],"is_preprint":false},{"year":2014,"finding":"ESE-1 (ELF3) upregulates GP73 expression in hepatocellular carcinoma cells by directly binding to the GP73 promoter, as demonstrated by ChIP. Both ESE-1 and GP73 are co-induced by IL-1β in vitro and in liver inflammation in vivo.","method":"ChIP, overexpression, siRNA knockdown, qRT-PCR, in vivo liver inflammation model","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding by ChIP, functional overexpression/KD, single lab","pmids":["25530841"],"is_preprint":false}],"current_model":"ELF3 (also known as ESE-1, ERT, ESX) is an epithelium-specific ETS transcription factor that contains an ETS DNA-binding domain and an A/T hook domain; it functions primarily as a sequence-specific transcriptional activator or repressor of target gene promoters (including TGF-β RII, SPRR2A, Ang-1, COX-2, COL2A1, IGF1, EREG, SLC31A1, HLA-C, and miR-141-3p), is induced in non-epithelial cells by pro-inflammatory cytokines (IL-1β, TNF-α, IL-17A) via NF-κB and IκBζ, physically interacts with the androgen receptor to inhibit its recruitment to target gene promoters, and—uniquely—can act in the cytoplasm via its SAR domain to transform mammary epithelial cells through a non-transcriptional mechanism; its activity and localization are regulated by nuclear export signals (CRM1-dependent NES in the pointed domain and DNA-binding domain), m6A mRNA modification (by WTAP), and upstream kinase signaling through a RIPK4→IRF6→GRHL3→ELF3 hierarchy in keratinocytes, with ELF3 also creating an autoregulatory positive feedback loop at its own superenhancer-regulated promoter in trophoblasts."},"narrative":{"mechanistic_narrative":"ELF3 (ESE-1/ERT) is an epithelium-specific ETS-family transcription factor that programs epithelial differentiation and links pro-inflammatory signaling to target-gene control through sequence-specific binding at ETS sites [PMID:9234700, PMID:9417054]. Its bipartite DNA-binding architecture combines an ETS domain with an A/T-hook, with the transactivation function residing in the amino terminus [PMID:9234700, PMID:9417054]. As a context-dependent regulator it activates differentiation and signaling genes—SPRR2A and keratin K12 in keratinocyte/corneal differentiation, the TGF-β type II receptor to restore TGF-β growth suppression, and angiopoietin-1 and COX-2 in inflammation—while acting as a direct repressor of others such as COL2A1, MMP-9, and the miR-141/miR-144 microRNAs that gate ZEB1-driven EMT [PMID:9234700, PMID:9417054, PMID:10644990, PMID:11025204, PMID:14715662, PMID:15794755, PMID:18044710, PMID:18302674, PMID:29523781, PMID:35616822]. ELF3 is itself an inflammatory effector: pro-inflammatory cytokines (IL-1β, TNF-α, IL-17A) induce its expression through NF-κB and the co-factor IκBζ, and Elf3-deficient mice show altered cytokine output and skewed dendritic-cell–driven T-cell differentiation [PMID:12746898, PMID:18475289, PMID:21948981, PMID:35792833]. A distinctive feature is compartment-dependent dual function: nuclear ELF3 acts transcriptionally and can drive apoptosis, whereas cytoplasmic ELF3 transforms mammary epithelial cells through its serine/aspartate-rich (SAR) domain by a non-transcriptional mechanism, with localization governed by an A/T-hook NLS and two CRM1-dependent nuclear export signals [PMID:15169914, PMID:21871131]. ELF3 also represses androgen receptor activity by physically interacting with AR and blocking its promoter recruitment [PMID:23435425]. Upstream, ELF3 is positioned within a RIPK4→IRF6→GRHL3 keratinocyte cornification hierarchy and is controlled by super-enhancers, m6A modification (WTAP), and autoregulatory feedback at its own promoter [PMID:27667567, PMID:33622787, PMID:38481803]. Across cancers ELF3 has both tumor-suppressive (TGF-β RII restoration, EREG/EGFR-mTORC1 repression) and oncogenic (LUAD amplification, ASCL1+ neuroendocrine super-enhancer network, hypoxic IGF1/VEGF angiogenesis) roles depending on tissue context [PMID:10644990, PMID:31780666, PMID:35695065, PMID:37345534, PMID:36840413].","teleology":[{"year":1997,"claim":"Established the founding identity of ELF3 as an epithelium-restricted ETS transcription factor with a unique two-domain DNA-binding architecture, answering what kind of regulatory protein it is.","evidence":"Molecular cloning, EMSA, and reporter assays on the SPRR2A promoter and Endo A enhancer","pmids":["9234700"],"confidence":"High","gaps":["Direct in vivo target repertoire not yet defined","Role of the A/T-hook versus ETS domain in target selection not dissected"]},{"year":1998,"claim":"Identified TGF-β type II receptor as a direct ELF3 target and mapped functional domains, connecting ELF3 to growth-suppressive signaling.","evidence":"Yeast one-hybrid, EMSA, reporter assays, and deletion mapping on the TGF-β RII promoter","pmids":["9417054"],"confidence":"High","gaps":["Physiological consequence of TGF-β RII activation not tested in this study"]},{"year":2000,"claim":"Demonstrated that ELF3 restores TGF-β growth-inhibitory signaling and reduces tumorigenicity, establishing a tumor-suppressive axis in breast cancer.","evidence":"Retroviral overexpression, Northern blot, and xenograft assays in Hs578t cells","pmids":["10644990"],"confidence":"High","gaps":["Whether endogenous ELF3 loss drives the tumor phenotype not addressed","Mechanism of TGF-β RII silencing not resolved"]},{"year":2000,"claim":"Linked ELF3 to epithelial differentiation programs beyond skin, showing it drives corneal keratin expression and is required for corneal epithelial differentiation.","evidence":"Reporter assays and antisense loss-of-function in corneal epithelial cells","pmids":["11025204"],"confidence":"Medium","gaps":["Antisense specificity limited","Direct binding to K12 element vs. indirect effect not separated"]},{"year":2003,"claim":"Defined how inflammation engages ELF3, showing IL-1β induces ELF3 via direct NF-κB binding to its promoter, casting ELF3 as a downstream inflammatory effector.","evidence":"Reporter mutants, EMSA supershift, adenoviral IκB, and ChIP in primary cells","pmids":["12746898"],"confidence":"High","gaps":["Downstream inflammatory targets not yet enumerated in this study"]},{"year":2003,"claim":"Showed ELF3 operates within multi-factor differentiation complexes, cooperating with Skn-1a to drive SPRR2A.","evidence":"Co-transfection reporter assays and domain mapping","pmids":["12624109"],"confidence":"Medium","gaps":["Physical interaction with Skn-1a not directly shown","Cooperativity not validated at endogenous loci"]},{"year":2004,"claim":"Defined ELF3 as a direct activator of pro-inflammatory/angiogenic genes (Ang-1, and later COX-2), expanding its inflammatory transcriptional program.","evidence":"Promoter mutagenesis, EMSA, transcriptional profiling, and dominant-negative assays","pmids":["14715662","15794755"],"confidence":"High","gaps":["In vivo requirement of ELF3 for Ang-1/COX-2 induction not tested"]},{"year":2004,"claim":"Revealed a compartment-specific dual mechanism: cytoplasmic ELF3 transforms via the SAR domain non-transcriptionally while nuclear ELF3 induces apoptosis transcriptionally.","evidence":"GFP localization, NLS/NES fusions, domain deletion, and transformation/apoptosis assays in mammary epithelial cells","pmids":["15169914"],"confidence":"High","gaps":["Cytoplasmic SAR-domain effector partners not identified","Endogenous relevance of cytoplasmic pool not established"]},{"year":2008,"claim":"Established ELF3 as a direct transcriptional repressor in addition to an activator, repressing COL2A1 and MMP-9 and extending the cytokine-driven NF-κB induction to airway epithelium.","evidence":"ChIP, EMSA, siRNA, reporter mapping, invasion/zymography assays, and Elf3 KO mice","pmids":["18044710","18302674","18475289"],"confidence":"High","gaps":["Determinants of activator vs. repressor mode at a given promoter not defined","Negative autoregulation mechanism partial"]},{"year":2008,"claim":"Connected ELF3 to drug-induced apoptosis via EGR-1 and showed pharmacological control of its nuclear translocation.","evidence":"EMSA, ChIP, reporter, siRNA, and nuclear translocation assays in colorectal cancer cells","pmids":["19074849"],"confidence":"High","gaps":["Signal coupling tolfenamic acid to ELF3 translocation not resolved"]},{"year":2011,"claim":"Mapped the NLS/NES architecture controlling ELF3 localization and pinpointed NES2 as essential for SAR-domain transformation.","evidence":"GFP localization, site-directed mutagenesis of NLS/NES motifs, and transformation assays","pmids":["21871131"],"confidence":"High","gaps":["Physiological signals regulating CRM1-dependent export not identified"]},{"year":2011,"claim":"Defined ELF3's organismal immune role, showing it controls dendritic-cell IL-12p40/IL-6 output and Th1/Th17 versus Th2 balance.","evidence":"Elf3 knockout mice, OVA airway models, ELISA, and flow cytometry","pmids":["21948981"],"confidence":"High","gaps":["Direct ELF3 binding at IL-12p40 not demonstrated","Cell-intrinsic vs extrinsic contributions not fully separated"]},{"year":2013,"claim":"Uncovered a non-ETS-DNA mechanism of action: ELF3 physically binds the androgen receptor and blocks its promoter recruitment, repressing AR signaling.","evidence":"Co-IP/pulldown, ChIP of AR recruitment, siRNA/overexpression, and xenografts in prostate cancer","pmids":["23435425"],"confidence":"High","gaps":["Interaction interface on ELF3/AR not mapped","Whether other nuclear receptors are similarly inhibited unknown"]},{"year":2016,"claim":"Placed ELF3 within an upstream keratinocyte cornification signaling hierarchy (RIPK4→IRF6→GRHL3→ELF3).","evidence":"Sequential siRNA epistasis, qRT-PCR, and Western blot in keratinocytes","pmids":["27667567"],"confidence":"Medium","gaps":["Direct vs. indirect regulation of ELF3 by IRF6/GRHL3 not distinguished","Single-lab epistasis"]},{"year":2018,"claim":"Defined ELF3's role in EMT control by repressing ZEB1-activating microRNAs and antagonizing Wnt/RAS signaling, revealing context-dependent pro- and anti-EMT effects.","evidence":"ChIP at miR-141-3p promoter, RNA-seq, siRNA, and migration/invasion assays in liver and colorectal cancer","pmids":["29523781","30148686"],"confidence":"Medium","gaps":["Opposing EMT directions across cancers not mechanistically reconciled","Direct binding shown only in some contexts"]},{"year":2019,"claim":"Demonstrated ELF3 can act as an amplified oncogenic driver dependent on tissue context in lung adenocarcinoma.","evidence":"Genomic copy-number/methylation analysis and functional knockdown with tumor growth readout","pmids":["31780666"],"confidence":"Medium","gaps":["Oncogenic transcriptional targets in LUAD not defined here","Mechanism of subtype specificity unresolved"]},{"year":2021,"claim":"Revealed super-enhancer and autoregulatory control of ELF3 plus a MED-coactivator interaction required for HLA-C expression in trophoblasts.","evidence":"ChIP-PCR, siRNA, ATAC-seq, single-cell RNA-seq, and wrenchnolol disruption of ELF3-MED23","pmids":["33622787"],"confidence":"High","gaps":["Generality of the autoregulatory loop beyond trophoblasts unknown","MED23 vs MED1 contributions not fully separated"]},{"year":2022,"claim":"Extended ELF3 functions to hypoxic angiogenesis (IGF1/VEGF) and to vertebrate ECM/tissue morphogenesis.","evidence":"siRNA, ELISA, angiogenesis/xenograft assays in ovarian cancer; morpholino and CRISPR knockdown phenotyping in zebrafish","pmids":["35695065","36383615"],"confidence":"Medium","gaps":["Direct ELF3 binding to IGF1 promoter not fully confirmed","ECM target genes downstream of Elf3 in zebrafish not directly bound"]},{"year":2023,"claim":"Consolidated ELF3 as a bidirectional cancer regulator: tumor-suppressive via direct EREG repression limiting EGFR/mTORC1, and oncogenic via a super-enhancer-driven network in ASCL1+ neuroendocrine carcinoma.","evidence":"Autochthonous KPCE mouse model, organoids, ChIP, CRISPR epistasis (gallbladder); ATAC-seq, CUT&Tag, and KD-RNA-seq (neuroendocrine carcinoma)","pmids":["37345534","36840413"],"confidence":"High","gaps":["What dictates suppressor vs. oncogene behavior across lineages unresolved","Cooperating factors in the NEC network not mapped"]},{"year":2024,"claim":"Identified post-transcriptional (m6A/WTAP) control of ELF3 and new direct targets driving fibroblast senescence (IRF8) and copper-dependent cell death (SLC31A1).","evidence":"m6A-seq, ChIP at IRF8 and SLC31A1 promoters, reporter assays, sh/siRNA, and in vivo aging/AKI models","pmids":["38481803","38462020"],"confidence":"Medium","gaps":["Reader/eraser logic of ELF3 m6A regulation incomplete","Single-lab target validation"]},{"year":null,"claim":"It remains unresolved what molecular switch determines ELF3's opposing transcriptional outputs—activator vs. repressor at a given promoter, and tumor-suppressor vs. oncogene across tissues—and how its nuclear/cytoplasmic partitioning is dynamically controlled in vivo.","evidence":"No single study in the corpus reconciles the context-dependent dual functions","pmids":[],"confidence":"Low","gaps":["No unified model of cofactor-dependent activator/repressor switching","Cytoplasmic SAR-domain effector pathway uncharacterized","Genome-wide direct binding map across cell types absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,9,10,12,18,20,23,29,32,33]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,12,23,32,33]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,13,17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8,17]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,9,12,23,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,11,16,28]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,4,19,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,22,26,29,30]}],"complexes":[],"partners":["AR","MED1","MED23","WTAP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P78545","full_name":"ETS-related transcription factor Elf-3","aliases":["E74-like factor 3","Epithelial-restricted with serine box","Epithelium-restricted Ets protein ESX","Epithelium-specific Ets transcription factor 1","ESE-1"],"length_aa":371,"mass_kda":41.5,"function":"Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters. Represses KRT4 promoter activity. Involved in mediating vascular inflammation. May play an important role in epithelial cell differentiation and tumorigenesis. May be a critical downstream effector of the ERBB2 signaling pathway. May be associated with mammary gland development and involution. Plays an important role in the regulation of transcription with TATA-less promoters in preimplantation embryos, which is essential in preimplantation development (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P78545/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ELF3","classification":"Not Classified","n_dependent_lines":18,"n_total_lines":1208,"dependency_fraction":0.014900662251655629},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ELF3","total_profiled":1310},"omim":[{"mim_id":"609596","title":"EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT K; EIF3K","url":"https://www.omim.org/entry/609596"},{"mim_id":"607394","title":"POU DOMAIN, CLASS 2, TRANSCRIPTION FACTOR 3; POU2F3","url":"https://www.omim.org/entry/607394"},{"mim_id":"605439","title":"ETS HOMOLOGOUS FACTOR; EHF","url":"https://www.omim.org/entry/605439"},{"mim_id":"603956","title":"CERVICAL CANCER","url":"https://www.omim.org/entry/603956"},{"mim_id":"602191","title":"E74-LIKE ETS TRANSCRIPTION FACTOR 3; ELF3","url":"https://www.omim.org/entry/602191"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":229.3}],"url":"https://www.proteinatlas.org/search/ELF3"},"hgnc":{"alias_symbol":["EPR-1","ESE-1","ERT"],"prev_symbol":["ESX"]},"alphafold":{"accession":"P78545","domains":[{"cath_id":"1.10.150.50","chopping":"1-14_60-134","consensus_level":"medium","plddt":75.8346,"start":1,"end":134},{"cath_id":"1.10.10.10","chopping":"274-368","consensus_level":"high","plddt":89.9661,"start":274,"end":368}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P78545","model_url":"https://alphafold.ebi.ac.uk/files/AF-P78545-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P78545-F1-predicted_aligned_error_v6.png","plddt_mean":64.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ELF3","jax_strain_url":"https://www.jax.org/strain/search?query=ELF3"},"sequence":{"accession":"P78545","fasta_url":"https://rest.uniprot.org/uniprotkb/P78545.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P78545/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P78545"}},"corpus_meta":[{"pmid":"19061637","id":"PMC_19061637","title":"COP1 and ELF3 control circadian function and photoperiodic flowering by regulating GI stability.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/19061637","citation_count":325,"is_preprint":false},{"pmid":"27665717","id":"PMC_27665717","title":"ESX secretion systems: mycobacterial evolution to counter host immunity.","date":"2016","source":"Nature reviews. Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/27665717","citation_count":302,"is_preprint":false},{"pmid":"9234700","id":"PMC_9234700","title":"Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9234700","citation_count":200,"is_preprint":false},{"pmid":"19155186","id":"PMC_19155186","title":"ESX/type VII secretion systems and their role in host-pathogen interaction.","date":"2009","source":"Current opinion in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19155186","citation_count":193,"is_preprint":false},{"pmid":"28119503","id":"PMC_28119503","title":"Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28119503","citation_count":190,"is_preprint":false},{"pmid":"18503637","id":"PMC_18503637","title":"ESX-1-dependent cytolysis in lysosome secretion and inflammasome activation during mycobacterial infection.","date":"2008","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18503637","citation_count":163,"is_preprint":false},{"pmid":"21957139","id":"PMC_21957139","title":"Mycobacterial secretion systems ESX-1 and ESX-5 play distinct roles in host cell death and inflammasome activation.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21957139","citation_count":119,"is_preprint":false},{"pmid":"9417054","id":"PMC_9417054","title":"A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-beta type II receptor.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9417054","citation_count":103,"is_preprint":false},{"pmid":"17908204","id":"PMC_17908204","title":"A unique Mycobacterium ESX-1 protein co-secretes with CFP-10/ESAT-6 and is necessary for inhibiting phagosome maturation.","date":"2007","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17908204","citation_count":102,"is_preprint":false},{"pmid":"30200227","id":"PMC_30200227","title":"ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer.","date":"2018","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30200227","citation_count":99,"is_preprint":false},{"pmid":"29523781","id":"PMC_29523781","title":"ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29523781","citation_count":94,"is_preprint":false},{"pmid":"24492980","id":"PMC_24492980","title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.","date":"2014","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/24492980","citation_count":91,"is_preprint":false},{"pmid":"10506207","id":"PMC_10506207","title":"Characterization of ESE-2, a novel ESE-1-related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10506207","citation_count":91,"is_preprint":false},{"pmid":"12746898","id":"PMC_12746898","title":"Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1.","date":"2003","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/12746898","citation_count":85,"is_preprint":false},{"pmid":"28199976","id":"PMC_28199976","title":"ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28199976","citation_count":80,"is_preprint":false},{"pmid":"24803520","id":"PMC_24803520","title":"Mycobacterial Esx-3 requires multiple components for iron acquisition.","date":"2014","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/24803520","citation_count":76,"is_preprint":false},{"pmid":"22157719","id":"PMC_22157719","title":"Multiple roles of the epithelium-specific ETS transcription factor, ESE-1, in development and disease.","date":"2011","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22157719","citation_count":72,"is_preprint":false},{"pmid":"31879349","id":"PMC_31879349","title":"The Mycobacterium marinum ESX-1 system mediates phagosomal permeabilization and type I interferon production via separable mechanisms.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31879349","citation_count":70,"is_preprint":false},{"pmid":"34160894","id":"PMC_34160894","title":"Bone marrow mesenchymal stem cell-derived exosomal miR-206 promotes osteoblast proliferation and differentiation in osteoarthritis by reducing Elf3.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34160894","citation_count":66,"is_preprint":false},{"pmid":"30633777","id":"PMC_30633777","title":"Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30633777","citation_count":65,"is_preprint":false},{"pmid":"22252989","id":"PMC_22252989","title":"Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.","date":"2012","source":"American journal of medical genetics. Part C, Seminars in medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22252989","citation_count":60,"is_preprint":false},{"pmid":"29803922","id":"PMC_29803922","title":"MiR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathway.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29803922","citation_count":60,"is_preprint":false},{"pmid":"18475289","id":"PMC_18475289","title":"Regulation of epithelium-specific Ets-like factors ESE-1 and ESE-3 in airway epithelial cells: potential roles in airway inflammation.","date":"2008","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18475289","citation_count":59,"is_preprint":false},{"pmid":"19074849","id":"PMC_19074849","title":"ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells.","date":"2008","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19074849","citation_count":58,"is_preprint":false},{"pmid":"34274947","id":"PMC_34274947","title":"The ELF3-regulated lncRNA UBE2CP3 is over-stabilized by RNA-RNA interactions and drives gastric cancer metastasis via miR-138-5p/ITGA2 axis.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34274947","citation_count":58,"is_preprint":false},{"pmid":"14715662","id":"PMC_14715662","title":"ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14715662","citation_count":54,"is_preprint":false},{"pmid":"31780666","id":"PMC_31780666","title":"Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31780666","citation_count":52,"is_preprint":false},{"pmid":"15794755","id":"PMC_15794755","title":"The Ets transcription factor ESE-1 mediates induction of the COX-2 gene by LPS in monocytes.","date":"2005","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/15794755","citation_count":51,"is_preprint":false},{"pmid":"15169914","id":"PMC_15169914","title":"The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15169914","citation_count":49,"is_preprint":false},{"pmid":"10644990","id":"PMC_10644990","title":"Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10644990","citation_count":47,"is_preprint":false},{"pmid":"18044710","id":"PMC_18044710","title":"ESE-1 is a potent repressor of type II collagen gene (COL2A1) transcription in human chondrocytes.","date":"2008","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18044710","citation_count":46,"is_preprint":false},{"pmid":"36457025","id":"PMC_36457025","title":"LncRNA ELF3-AS1 inhibits gastric cancer by forming a negative feedback loop with SNAI2 and regulates ELF3 mRNA stability via interacting with ILF2/ILF3 complex.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/36457025","citation_count":46,"is_preprint":false},{"pmid":"27200304","id":"PMC_27200304","title":"Modular Organization of the ESX-5 Secretion System in Mycobacterium tuberculosis.","date":"2016","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/27200304","citation_count":45,"is_preprint":false},{"pmid":"11025204","id":"PMC_11025204","title":"Ets family transcription factor ESE-1 is expressed in corneal epithelial cells and is involved in their differentiation.","date":"2000","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11025204","citation_count":43,"is_preprint":false},{"pmid":"31298207","id":"PMC_31298207","title":"ESX/Type VII Secretion Systems-An Important Way Out for Mycobacterial Proteins.","date":"2019","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/31298207","citation_count":41,"is_preprint":false},{"pmid":"35671426","id":"PMC_35671426","title":"Proteo-genetic analysis reveals clear hierarchy of ESX-1 secretion in Mycobacterium marinum.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35671426","citation_count":39,"is_preprint":false},{"pmid":"21466982","id":"PMC_21466982","title":"Developmental validation of the PowerPlex® ESX 16 and PowerPlex® ESX 17 Systems.","date":"2011","source":"Forensic science international. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21466982","citation_count":38,"is_preprint":false},{"pmid":"24364000","id":"PMC_24364000","title":"ESX-1-induced apoptosis during mycobacterial infection: to be or not to be, that is the question.","date":"2013","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/24364000","citation_count":37,"is_preprint":false},{"pmid":"24610712","id":"PMC_24610712","title":"A novel ESX-1 locus reveals that surface-associated ESX-1 substrates mediate virulence in Mycobacterium marinum.","date":"2014","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/24610712","citation_count":37,"is_preprint":false},{"pmid":"35695065","id":"PMC_35695065","title":"Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R.","date":"2022","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/35695065","citation_count":35,"is_preprint":false},{"pmid":"33452244","id":"PMC_33452244","title":"Pore-forming Esx proteins mediate toxin secretion by Mycobacterium tuberculosis.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33452244","citation_count":35,"is_preprint":false},{"pmid":"10049594","id":"PMC_10049594","title":"Genomic organization of the human ELF3 (ESE-1/ESX) gene, a member of the Ets transcription factor family, and identification of a functional promoter.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10049594","citation_count":33,"is_preprint":false},{"pmid":"28461452","id":"PMC_28461452","title":"Esx Systems and the Mycobacterial Cell Envelope: What's the Connection?","date":"2017","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/28461452","citation_count":32,"is_preprint":false},{"pmid":"32878966","id":"PMC_32878966","title":"Modeling Tubercular ESX-1 Secretion Using Mycobacterium marinum.","date":"2020","source":"Microbiology and molecular biology reviews : MMBR","url":"https://pubmed.ncbi.nlm.nih.gov/32878966","citation_count":32,"is_preprint":false},{"pmid":"33174865","id":"PMC_33174865","title":"ESX secretion system: The gatekeepers of mycobacterial survivability and pathogenesis.","date":"2020","source":"European journal of microbiology & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33174865","citation_count":32,"is_preprint":false},{"pmid":"12624109","id":"PMC_12624109","title":"Distinct functional interactions of human Skn-1 isoforms with Ese-1 during keratinocyte terminal differentiation.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12624109","citation_count":31,"is_preprint":false},{"pmid":"33290182","id":"PMC_33290182","title":"Mycobacterium tuberculosis ESX-1-secreted substrate protein EspC promotes mycobacterial survival through endoplasmic reticulum stress-mediated apoptosis.","date":"2021","source":"Emerging microbes & infections","url":"https://pubmed.ncbi.nlm.nih.gov/33290182","citation_count":30,"is_preprint":false},{"pmid":"36864480","id":"PMC_36864480","title":"The ELF3 transcription factor is associated with an epithelial phenotype and represses epithelial-mesenchymal transition.","date":"2023","source":"Journal of biological engineering","url":"https://pubmed.ncbi.nlm.nih.gov/36864480","citation_count":30,"is_preprint":false},{"pmid":"30833360","id":"PMC_30833360","title":"A New ESX-1 Substrate in Mycobacterium marinum That Is Required for Hemolysis but Not Host Cell Lysis.","date":"2019","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/30833360","citation_count":30,"is_preprint":false},{"pmid":"38462020","id":"PMC_38462020","title":"The copper transporter, SLC31A1, transcriptionally activated by ELF3, imbalances copper homeostasis to exacerbate cisplatin-induced acute kidney injury through mitochondrial dysfunction.","date":"2024","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/38462020","citation_count":29,"is_preprint":false},{"pmid":"37922311","id":"PMC_37922311","title":"Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37922311","citation_count":28,"is_preprint":false},{"pmid":"27859892","id":"PMC_27859892","title":"Discovery of the type VII ESX-1 secretion needle?","date":"2016","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/27859892","citation_count":28,"is_preprint":false},{"pmid":"32184351","id":"PMC_32184351","title":"Modification of a PE/PPE substrate pair reroutes an Esx substrate pair from the mycobacterial ESX-1 type VII secretion system to the ESX-5 system.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32184351","citation_count":28,"is_preprint":false},{"pmid":"30955952","id":"PMC_30955952","title":"Fabry's disease and stroke: Effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis.","date":"2019","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/30955952","citation_count":25,"is_preprint":false},{"pmid":"35792833","id":"PMC_35792833","title":"IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via IκBζ-dependent induction of ELF3.","date":"2023","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35792833","citation_count":25,"is_preprint":false},{"pmid":"30673778","id":"PMC_30673778","title":"Integrated transcriptomic and proteomic analysis of pathogenic mycobacteria and their esx-1 mutants reveal secretion-dependent regulation of ESX-1 substrates and WhiB6 as a transcriptional regulator.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30673778","citation_count":24,"is_preprint":false},{"pmid":"23435425","id":"PMC_23435425","title":"ELF3 is a repressor of androgen receptor action in prostate cancer cells.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23435425","citation_count":24,"is_preprint":false},{"pmid":"18302674","id":"PMC_18302674","title":"ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression.","date":"2008","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18302674","citation_count":23,"is_preprint":false},{"pmid":"35616822","id":"PMC_35616822","title":"Downregulation of LINC00886 facilitates epithelial-mesenchymal transition through SIRT7/ELF3/miR-144 pathway in esophageal squamous cell carcinoma.","date":"2022","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/35616822","citation_count":23,"is_preprint":false},{"pmid":"29941598","id":"PMC_29941598","title":"Direct cell-cell contact activates SigM to express the ESX-4 secretion system in Mycobacterium smegmatis.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29941598","citation_count":23,"is_preprint":false},{"pmid":"30419243","id":"PMC_30419243","title":"Structural Variability of EspG Chaperones from Mycobacterial ESX-1, ESX-3, and ESX-5 Type VII Secretion Systems.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30419243","citation_count":22,"is_preprint":false},{"pmid":"21948981","id":"PMC_21948981","title":"Elf3 regulates allergic airway inflammation by controlling dendritic cell-driven T cell differentiation.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21948981","citation_count":22,"is_preprint":false},{"pmid":"31686842","id":"PMC_31686842","title":"LncRNA ELF3-AS1 is involved in the regulation of oral squamous cell carcinoma cell proliferation by reprogramming glucose metabolism.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31686842","citation_count":22,"is_preprint":false},{"pmid":"25738547","id":"PMC_25738547","title":"Gibberellin driven growth in elf3 mutants requires PIF4 and PIF5.","date":"2015","source":"Plant signaling & behavior","url":"https://pubmed.ncbi.nlm.nih.gov/25738547","citation_count":22,"is_preprint":false},{"pmid":"32253249","id":"PMC_32253249","title":"The ESX-1 Virulence Factors Downregulate miR-147-3p in Mycobacterium marinum-Infected Macrophages.","date":"2020","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/32253249","citation_count":21,"is_preprint":false},{"pmid":"39025063","id":"PMC_39025063","title":"A pair of E3 ubiquitin ligases control immunity and flowering by targeting different ELF3 proteins in rice.","date":"2024","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/39025063","citation_count":21,"is_preprint":false},{"pmid":"24897114","id":"PMC_24897114","title":"Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24897114","citation_count":21,"is_preprint":false},{"pmid":"38614305","id":"PMC_38614305","title":"The function of the ELF3 gene and its mechanism in cancers.","date":"2024","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38614305","citation_count":20,"is_preprint":false},{"pmid":"29555701","id":"PMC_29555701","title":"Esx Paralogs Are Functionally Equivalent to ESX-1 Proteins but Are Dispensable for Virulence in Mycobacterium marinum.","date":"2018","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/29555701","citation_count":20,"is_preprint":false},{"pmid":"30148686","id":"PMC_30148686","title":"ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30148686","citation_count":20,"is_preprint":false},{"pmid":"33622787","id":"PMC_33622787","title":"ELF3 activated by a superenhancer and an autoregulatory feedback loop is required for high-level HLA-C expression on extravillous trophoblasts.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33622787","citation_count":20,"is_preprint":false},{"pmid":"35005535","id":"PMC_35005535","title":"Crosstalk between the ancestral type VII secretion system ESX-4 and other T7SS in Mycobacterium marinum.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35005535","citation_count":20,"is_preprint":false},{"pmid":"36409073","id":"PMC_36409073","title":"The ESX-1 Substrate PPE68 Has a Key Function in ESX-1-Mediated Secretion in Mycobacterium marinum.","date":"2022","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/36409073","citation_count":19,"is_preprint":false},{"pmid":"21871131","id":"PMC_21871131","title":"Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism.","date":"2011","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21871131","citation_count":19,"is_preprint":false},{"pmid":"34975306","id":"PMC_34975306","title":"Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis.","date":"2022","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34975306","citation_count":18,"is_preprint":false},{"pmid":"38481803","id":"PMC_38481803","title":"WTAP Mediated N6-methyladenosine RNA Modification of ELF3 Drives Cellular Senescence by Upregulating IRF8.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38481803","citation_count":17,"is_preprint":false},{"pmid":"11313868","id":"PMC_11313868","title":"Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TGF-beta type II receptor expression.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11313868","citation_count":17,"is_preprint":false},{"pmid":"34337436","id":"PMC_34337436","title":"Priming mycobacterial ESX-secreted protein B to form a channel-like structure.","date":"2021","source":"Current research in structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/34337436","citation_count":17,"is_preprint":false},{"pmid":"34006663","id":"PMC_34006663","title":"ESX-1-Independent Horizontal Gene Transfer by Mycobacterium tuberculosis Complex Strains.","date":"2021","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/34006663","citation_count":16,"is_preprint":false},{"pmid":"25530841","id":"PMC_25530841","title":"Epithelium-Specific ETS (ESE)-1 upregulated GP73 expression in hepatocellular carcinoma cells.","date":"2014","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/25530841","citation_count":16,"is_preprint":false},{"pmid":"27667567","id":"PMC_27667567","title":"A novel regulatory relationship between RIPK4 and ELF3 in keratinocytes.","date":"2016","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/27667567","citation_count":16,"is_preprint":false},{"pmid":"36840413","id":"PMC_36840413","title":"An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma.","date":"2023","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/36840413","citation_count":16,"is_preprint":false},{"pmid":"37000471","id":"PMC_37000471","title":"High Bacillary Burden and the ESX-1 Type VII Secretion System Promote MHC Class I Presentation by Mycobacterium tuberculosis-Infected Macrophages to CD8 T Cells.","date":"2023","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/37000471","citation_count":16,"is_preprint":false},{"pmid":"36791560","id":"PMC_36791560","title":"Virus-like nanoparticles as enzyme carriers for Enzyme Replacement Therapy (ERT).","date":"2023","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/36791560","citation_count":15,"is_preprint":false},{"pmid":"35960766","id":"PMC_35960766","title":"The ESX-4 substrates, EsxU and EsxT, modulate Mycobacterium abscessus fitness.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/35960766","citation_count":14,"is_preprint":false},{"pmid":"12099668","id":"PMC_12099668","title":"The role of ERT/HRT.","date":"2002","source":"Best practice & research. Clinical obstetrics & gynaecology","url":"https://pubmed.ncbi.nlm.nih.gov/12099668","citation_count":13,"is_preprint":false},{"pmid":"20689519","id":"PMC_20689519","title":"The counter-regulatory effects of ESE-1 during angiotensin II-mediated vascular inflammation and remodeling.","date":"2010","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/20689519","citation_count":13,"is_preprint":false},{"pmid":"37345534","id":"PMC_37345534","title":"ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway.","date":"2023","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37345534","citation_count":12,"is_preprint":false},{"pmid":"37879428","id":"PMC_37879428","title":"ESX-3 secretion system in Mycobacterium: An overview.","date":"2023","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/37879428","citation_count":12,"is_preprint":false},{"pmid":"39813329","id":"PMC_39813329","title":"Single-cell analysis reveals Mycobacterium tuberculosis ESX-1-mediated accumulation of permissive macrophages in infected mouse lungs.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/39813329","citation_count":11,"is_preprint":false},{"pmid":"39873486","id":"PMC_39873486","title":"Frequently arising ESX-1-associated phase variants influence Mycobacterium tuberculosis fitness in the presence of host and antibiotic pressures.","date":"2025","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/39873486","citation_count":11,"is_preprint":false},{"pmid":"27744102","id":"PMC_27744102","title":"A metabolomics investigation of the function of the ESX-1 gene cluster in mycobacteria.","date":"2016","source":"Microbial pathogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27744102","citation_count":11,"is_preprint":false},{"pmid":"14997048","id":"PMC_14997048","title":"Partially unspliced and fully spliced ELF3 mRNA, including a new Alu element in human breast cancer.","date":"2004","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/14997048","citation_count":11,"is_preprint":false},{"pmid":"36830581","id":"PMC_36830581","title":"Dysregulation of Mycobacterium marinum ESX-5 Secretion by Novel 1,2,4-oxadiazoles.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36830581","citation_count":10,"is_preprint":false},{"pmid":"31843799","id":"PMC_31843799","title":"Polarly Localized EccE1 Is Required for ESX-1 Function and Stabilization of ESX-1 Membrane Proteins in Mycobacterium tuberculosis.","date":"2020","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/31843799","citation_count":10,"is_preprint":false},{"pmid":"34558604","id":"PMC_34558604","title":"IMB-BZ as an Inhibitor Targeting ESX-1 Secretion System to Control Mycobacterial Infection.","date":"2022","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34558604","citation_count":10,"is_preprint":false},{"pmid":"39900631","id":"PMC_39900631","title":"Deletion of ESX-3 and ESX-4 secretion systems in Mycobacterium abscessus results in highly impaired pathogenicity.","date":"2025","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/39900631","citation_count":9,"is_preprint":false},{"pmid":"37017530","id":"PMC_37017530","title":"Intragranuloma Accumulation and Inflammatory Differentiation of Neutrophils Underlie Mycobacterial ESX-1-Dependent Immunopathology.","date":"2023","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/37017530","citation_count":9,"is_preprint":false},{"pmid":"35258410","id":"PMC_35258410","title":"LINC00472 suppresses oral squamous cell carcinoma growth by targeting miR-455-3p/ELF3 axis.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35258410","citation_count":9,"is_preprint":false},{"pmid":"36383615","id":"PMC_36383615","title":"Elf3 deficiency during zebrafish development alters extracellular matrix organization and disrupts tissue morphogenesis.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36383615","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52592,"output_tokens":9284,"usd":0.148518,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19299,"output_tokens":5912,"usd":0.122148,"stage2_stop_reason":"end_turn"},"total_usd":0.270666,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"ELF3 (ESE-1) was identified as an epithelium-specific ETS transcription factor containing two DNA-binding domains: an ETS domain and an A/T hook domain (found in HMG proteins). It binds with high affinity to ETS binding sites in the SPRR2A promoter and transactivates SPRR2A and the Endo A gene enhancer, establishing it as a transcriptional activator of keratinocyte differentiation target genes.\",\n      \"method\": \"Molecular cloning, electrophoretic mobility shift assay (EMSA), transient transfection/luciferase reporter assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — original characterization with multiple orthogonal methods (EMSA, reporter assay, expression profiling), replicated across subsequent studies\",\n      \"pmids\": [\"9234700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ELF3 (ERT) activates transcription of the TGF-β type II receptor (RII) gene by binding to ETS binding sites in the TGF-β RII promoter (response element at +13 to +24 and multiple sites between -1816 and -82). Deletion mapping showed the transactivation domain resides in the amino terminus and the DNA-binding domain in the carboxyl-terminal region.\",\n      \"method\": \"Yeast one-hybrid screening, luciferase reporter assay, EMSA, deletion mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (yeast one-hybrid, EMSA, reporter assay, domain mapping) in a single study, replicated by subsequent work\",\n      \"pmids\": [\"9417054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The human ELF3 gene contains nine exons spanning ~5.8 kb. A 1.5-kb fragment of the 5' upstream region acts as a functional promoter in epithelial cell lines, containing TATA and CCAAT boxes and potential binding sites for Ets factors and NF-κB.\",\n      \"method\": \"Genomic cloning, transfection experiments with promoter-reporter constructs\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter characterization by transfection, single lab, two methods\",\n      \"pmids\": [\"10049594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ELF3 (ERT) overexpression in Hs578t breast cancer cells induces endogenous TGF-β type II receptor mRNA and protein expression, restores TGF-β growth inhibitory signaling (~50% growth reduction with exogenous TGF-β1), and reduces tumorigenicity in athymic mice, confirming ELF3 as a transcriptional activator of TGF-β RII in vivo.\",\n      \"method\": \"Retroviral overexpression, Northern blot, luciferase reporter assay, xenograft mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional rescue in cell lines and in vivo xenograft, multiple orthogonal methods, consistent with in vitro mechanistic data from prior study\",\n      \"pmids\": [\"10644990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ELF3 (ESE-1) is expressed in corneal epithelial cells and is upregulated during differentiation. It transactivates the regulatory element of cornea-specific K12 keratin. Introduction of ESE-1 antisense RNA in immortalized human corneal epithelial cells impairs their differentiation.\",\n      \"method\": \"Northern blot, luciferase reporter assay, antisense RNA loss-of-function\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus antisense loss-of-function with differentiation phenotype, single lab\",\n      \"pmids\": [\"11025204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Loss of ELF3 (ERT) expression in gastric cancer cell lines with undetectable TGF-β RII mRNA is linked to inactivation of a sequence-specific DNA binding protein (nuclear protein complex) that recognizes the ERT promoter element ESE (-186 to -177), suggesting that loss of this transcriptional activator contributes to silencing of ERT and subsequent TGF-β resistance.\",\n      \"method\": \"Promoter cloning, EMSA, transient transfection, deletion analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — EMSA and reporter assay, single lab, mechanism partially defined\",\n      \"pmids\": [\"11313868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Induction of ELF3 (ESE-1) gene expression by IL-1β in synovial fibroblasts, chondrocytes, osteoblasts, and monocytes requires activation of NF-κB and binding of p50 and p65 NF-κB family members to a high-affinity NF-κB binding site in the ESE-1 promoter. Overexpression of IκB using adenoviral vector blocked IL-1β-induced ESE-1 mRNA expression. ChIP confirmed NF-κB binds the ESE-1 promoter in vivo.\",\n      \"method\": \"Luciferase reporter assay with promoter mutants, EMSA with supershift assay, adenoviral IκB overexpression, chromatin immunoprecipitation (ChIP)\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (reporter assay, EMSA, ChIP, adenoviral KD), functionally confirmed in primary cells\",\n      \"pmids\": [\"12746898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ELF3 (ESE-1/Ese-1) cooperates functionally with the Skn-1a isoform of Oct-11 to drive SPRR2A expression in keratinocyte terminal differentiation. This cooperativity depends on an N-terminal pointed-like domain in Skn-1a; the Skn-1d1 isoform counteracts this cooperativity. Identifies ELF3 as part of a multi-factor complex regulating keratinocyte differentiation.\",\n      \"method\": \"Transient co-transfection reporter assays, domain deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cooperativity in reporter assays with domain mapping, single lab\",\n      \"pmids\": [\"12624109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ELF3 (ESE-1) protein is cytoplasmic in human breast cancer cells. Stably expressed GFP-ESE-1 transforms MCF-12A human mammary epithelial cells via a cytoplasmic, non-transcriptional mechanism mediated by the unique 40-amino acid serine/aspartic acid-rich (SAR) domain. Nuclear localization of ESE-1 induces apoptosis via a transcription-dependent mechanism. Fusion of an NLS to ESE-1 or SAR domain inhibits transforming capacity.\",\n      \"method\": \"Stable transfection, GFP subcellular localization, NLS/NES fusion constructs, apoptosis assays, domain deletion analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (stable transfection, domain mapping, NLS/NES manipulation, apoptosis readout), defines two distinct mechanistic functions by subcellular compartment\",\n      \"pmids\": [\"15169914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ELF3 (ESE-1) is a novel transcriptional mediator of angiopoietin-1 (Ang-1) expression in the setting of inflammation. ESE-1 binds to specific ETS sites within the Ang-1 promoter that are required for transactivation; mutation of a high-affinity ESE-1 binding site markedly reduces Ang-1 transactivation and cytokine inducibility. Transcriptional profiling confirmed direct induction of endogenous Ang-1 by ESE-1.\",\n      \"method\": \"Transient transfection reporter assay, site-directed mutagenesis of promoter, EMSA, transcriptional profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis of binding sites, EMSA, and transcriptional profiling with multiple orthogonal methods in single study\",\n      \"pmids\": [\"14715662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ELF3 (ESE-1) binds to multiple ETS sites on the COX-2 promoter and activates COX-2 expression in response to LPS and pro-inflammatory cytokines in monocytes/macrophages. Mutation of ETS sites in the COX-2 promoter or overexpression of dominant-negative ESE-1 inhibits LPS-mediated COX-2 induction. ESE-1's effect is enhanced by cooperation with NF-κB and NFAT.\",\n      \"method\": \"Luciferase reporter assay, promoter mutagenesis, EMSA, dominant-negative overexpression, co-transfection\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — promoter mutagenesis, dominant-negative, EMSA, multiple orthogonal methods, single lab but thorough mechanistic dissection\",\n      \"pmids\": [\"15794755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ELF3 (ESE-1) expression in airway epithelial cells is upregulated by IL-1β and TNF-α via NF-κB activation. ESE-1 also upregulates ESE-3 expression and downregulates its own induction by cytokines (negative autoregulation). In Elf3 knockout mice, IL-6 expression is downregulated following inflammatory stimulation.\",\n      \"method\": \"NF-κB promoter analysis, transfection, siRNA, Elf3 knockout mouse\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — promoter characterization, KO mouse with defined cytokine phenotype, in vitro and in vivo methods, replicated NF-κB mechanism\",\n      \"pmids\": [\"18475289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ELF3 (ESE-1) is a potent transcriptional repressor of the type II collagen gene (COL2A1) in chondrocytes in response to IL-1β, via NF-κB-dependent binding to tandem ETS sites at -403/-381 bp in the COL2A1 promoter. ChIP confirmed IL-1β-induced ESE-1 binding to the COL2A1 promoter in vivo. ETS-1, by contrast, activates COL2A1 and blocks IL-1β inhibition.\",\n      \"method\": \"Transient co-transfection, siRNA, ChIP, EMSA, promoter deletion analysis\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP, EMSA, siRNA, reporter with deletion mapping, multiple orthogonal methods\",\n      \"pmids\": [\"18044710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ELF3 (ESE-1) mediates tolfenamic acid-induced EGR-1 expression and apoptosis in colorectal cancer cells. ESE-1 binds to an ETS binding site at -400/-394 bp in the EGR-1 promoter (confirmed by EMSA and ChIP), and tolfenamic acid promotes nuclear translocation of ESE-1. Silencing ESE-1 attenuates tolfenamic acid-induced EGR-1 expression and apoptosis.\",\n      \"method\": \"EMSA, ChIP, luciferase reporter assay, siRNA knockdown, nuclear translocation assay\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — EMSA, ChIP, siRNA, reporter assay, and localization experiment in a single mechanistically thorough study\",\n      \"pmids\": [\"19074849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ELF3 (ESE-1) suppresses invasion of oral squamous cell carcinoma cells by transcriptionally repressing MMP-9 via an ETS binding site in the MMP-9 promoter. ESE-1 transfection reduces invasion activity and 92 kDa gelatinolytic activity, and luciferase/mutation analysis confirmed that the ETS binding site in the MMP-9 promoter mediates this suppression.\",\n      \"method\": \"Transfection, invasion assay, gelatin zymography, Northern blot, luciferase assay, mutation analysis\",\n      \"journal\": \"Oral diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional invasion assay, luciferase/mutation analysis, single lab with multiple methods\",\n      \"pmids\": [\"18302674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ELF3 (ESE-1) plays a counter-regulatory role in angiotensin II (Ang II)-mediated vascular inflammation and remodeling. ESE-1 KO mice show exaggerated intimal medial thickness, perivascular fibrosis, T cell and macrophage infiltration, greater PCNA staining, blunted NOS2 (iNOS) induction, and an exaggerated systolic blood pressure response to Ang II compared to wild-type controls.\",\n      \"method\": \"ESE-1 knockout mice, Ang II infusion model, histology, immunostaining\",\n      \"journal\": \"American journal of hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with defined vascular phenotype, single lab, multiple histological readouts but no in vitro mechanistic dissection\",\n      \"pmids\": [\"20689519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Elf3 regulates allergic airway inflammation by controlling dendritic cell (DC)-driven T cell differentiation. Elf3−/− mice show impaired IL-6 and IL-12 production by DCs, impaired Th1 and Th17 differentiation, and exaggerated Th2 responses with increased IgE. The impairment of IL-12 production was attributed to impaired IL-12p40 gene induction in Elf3-deficient DCs.\",\n      \"method\": \"Elf3 knockout mice, OVA sensitization/challenge models, ELISA, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse with multiple defined cellular and molecular phenotypes, in vivo and ex vivo methods, identifies IL-12p40 as a specific downstream target\",\n      \"pmids\": [\"21948981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ESE-1 (ELF3) SAR domain-mediated mammary cell transformation occurs exclusively in the cytoplasm. NLS mapped to six basic amino acids (242HGKRRR247) in the AT-hook domain. Two CRM1-dependent NES motifs were identified: NES1 in the pointed domain (102LCNCALEELRL112) and NES2 in the DNA binding domain (275LWEFIRDILI284). Site-specific mutation of NES2 abrogates transforming activity. The SAR domain is accessible for protein-protein interactions.\",\n      \"method\": \"GFP reporter subcellular localization, site-directed mutagenesis, NLS/NES fusion constructs, transformation assay\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — systematic domain mapping with site-directed mutagenesis and GFP localization reporters, multiple constructs and functional readouts\",\n      \"pmids\": [\"21871131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ELF3 is a repressor of androgen receptor (AR) transcriptional activity in prostate cancer cells. ELF3 physically interacts with AR (biochemical pulldown), and this interaction inhibits recruitment of AR to androgen response elements within target gene promoters. ELF3 knockdown increases AR transcriptional activity and promotes cell migration; ELF3 overexpression inhibits tumor growth in vitro and in xenograft models.\",\n      \"method\": \"Reporter-based transfection assays, endogenous AR target gene qPCR, siRNA knockdown, co-immunoprecipitation/pulldown, ChIP, xenograft mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — physical interaction demonstrated, ChIP showing impaired AR recruitment, functional rescue/KD with xenograft validation, multiple orthogonal methods\",\n      \"pmids\": [\"23435425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RIPK4 is upstream of ELF3 in keratinocytes: RIPK4 is required for PMA-inducible ELF3 gene expression. RIPK4 acts via phosphorylation and activation of IRF6, and IRF6 in turn regulates ELF3 expression. GRHL3, a downstream target of IRF6, also contributes to ELF3 regulation. ELF3 in this pathway regulates SPRR1A, SPRR1B, and TGM1 expression during keratinocyte cornification.\",\n      \"method\": \"siRNA knockdown of RIPK4, IRF6, GRHL3; qRT-PCR; Western blot\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis by sequential siRNA knockdown, single lab with multiple targets validated\",\n      \"pmids\": [\"27667567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ELF3 promotes EMT in hepatocellular carcinoma by transcriptionally repressing miR-141-3p, thereby de-repressing ZEB1. ChIP assays showed ELF3 binds the miR-141-3p promoter to suppress its transcription. ELF3 knockdown reverses EMT via miR-141-3p upregulation and ZEB1 repression.\",\n      \"method\": \"Gain/loss-of-function studies, ChIP assay, Western blot, migration/invasion assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct promoter binding, functional rescue experiments, single lab\",\n      \"pmids\": [\"29523781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ELF3 is a negative regulator of EMT transcription factor ZEB1 through its function as an antagonist of Wnt and RAS oncogenic signaling in colorectal cancer cells. ELF3 expression is reduced in response to oncogenic signaling (mutant β-catenin, inducible mutant RAS) and is anti-correlated with ZEB1 and EMT markers.\",\n      \"method\": \"RNA-Seq, siRNA, Western blot, analysis of colorectal cancer TCGA datasets, tumor/normal protein localization\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — RNA-Seq combined with siRNA functional validation, but pathway epistasis indirect; single lab\",\n      \"pmids\": [\"30148686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ELF3 is amplified at chromosome 1q32.1 in lung adenocarcinoma (LUAD), and ELF3 expression is required for tumor growth. Gene dosage and promoter hypomethylation affect the locus in up to 80% of LUAD analyzed. Pan-cancer network analysis supports subtype and tissue specificity of ELF3's oncogenic role in LUAD.\",\n      \"method\": \"Genomic analysis, functional KD in LUAD cells, pan-cancer expression network analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and functional evidence (KD with tumor growth readout), single lab, multiple data types\",\n      \"pmids\": [\"31780666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ELF3 is required for high-level HLA-C expression on extravillous trophoblasts (EVTs). ELF3 and MED1 bind to the proximal HLA-C promoter region (confirmed by ChIP-PCR). ELF3 creates an autoregulatory positive feedback loop by binding its own promoter. The ELF3 gene is regulated by a superenhancer spanning >5 Mb (identified by ATAC-seq and JQ1 sensitivity). The small molecule wrenchnolol blocks ELF3-MED23 interaction, disrupting the feedback loop and downregulating HLA-C.\",\n      \"method\": \"ChIP-PCR, siRNA knockdown, ATAC-seq, wrenchnolol treatment, single-cell RNA-seq\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP, siRNA, pharmacological inhibition, ATAC-seq, multiple orthogonal methods defining autoregulation and co-activator interaction\",\n      \"pmids\": [\"33622787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ELF3 is transcriptionally identified as a direct repressor of lncRNA UBE2CP3 in gastric cancer. ELF3 downregulation (via SNAI2 repression of ELF3) leads to UBE2CP3 upregulation, which promotes cancer progression via a miR-138-5p/ITGA2 ceRNA axis.\",\n      \"method\": \"ChIP, luciferase reporter assay, transcriptome sequencing, rescue experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct binding to UBE2CP3 regulatory region, functional rescue, single lab\",\n      \"pmids\": [\"34274947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In esophageal squamous cell carcinoma, ELF3 promotes EMT by binding to the miR-144 promoter to suppress miR-144-3p transcription, thereby de-repressing ZEB1 and ZEB2. The lncRNA LINC00886, acting via SIRT7-mediated H3K18 deacetylation at the ELF3 promoter, suppresses ELF3 expression, placing SIRT7 as an upstream epigenetic writer controlling ELF3.\",\n      \"method\": \"ChIP (for ELF3 binding to miR-144 promoter and SIRT7/H3K18ac at ELF3 promoter), luciferase reporter, siRNA, Western blot\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP data for ELF3 binding to miR-144 promoter and epigenetic regulation of ELF3 locus, single lab\",\n      \"pmids\": [\"35616822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ELF3 functions as a transcription factor for IGF1 in epithelial ovarian cancer under hypoxia. ELF3-mediated increase in IGF1 and VEGF secretion promotes endothelial cell proliferation, migration, and tumor angiogenesis. ELF3 silencing under hypoxia significantly attenuated angiogenic activity and tumorigenesis in ex vivo and xenograft models.\",\n      \"method\": \"siRNA knockdown, IGF1/VEGF ELISA, endothelial cell proliferation/migration assays, ex vivo and xenograft models\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional KD with in vitro and in vivo angiogenesis readouts; ELF3 as IGF1 transcription factor inferred but direct promoter binding confirmation limited in abstract\",\n      \"pmids\": [\"35695065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ELF3 deficiency in zebrafish disrupts extracellular matrix (ECM) organization and tissue morphogenesis. Elf3 knockdown (morpholino and CRISPR/Cas9) produces short, bent larvae with notochord, craniofacial cartilage, fin, and neural defects, with disorganized ECM in fin and notochord, and dysregulation of genes encoding ECM proteins and matrix metalloproteinases (MMPs).\",\n      \"method\": \"Morpholino antisense knockdown, CRISPR/Cas9 knockdown, in situ hybridization, histology, gene expression analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent KD methods in zebrafish with specific developmental and molecular phenotypes, single lab\",\n      \"pmids\": [\"36383615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ELF3 is required for proinflammatory mediator induction by the synergistic action of IL-17A and TNF in synovial fibroblasts. ELF3 expression is induced by the NF-κB co-factor IκBζ (synthesized in response to IL-17A+TNF), and requires NF-κB signaling and C/EBPβ. siRNA depletion of ELF3 attenuates cytokine and MMP induction. Overexpression of ELF3 or IκBζ synergizes with TNF to upregulate CCL8, and ELF3 depletion abrogates CCL8 induction by IκBζ+TNF.\",\n      \"method\": \"siRNA knockdown, transient overexpression, signaling inhibitors, qRT-PCR, HEK293 and primary synovial fibroblast experiments\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (sequential siRNA), overexpression rescue, single lab with multiple cell types\",\n      \"pmids\": [\"35792833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ELF3 suppresses gallbladder cancer development by directly repressing epiregulin (EREG) transcription, thereby reducing EGFR/mTORC1 signaling. In vivo (KPCE mouse model), loss of Elf3 leads to upregulation of Ereg and EGFR/mTORC1. ChIP of Elf3-overexpressing organoids confirmed direct ELF3 binding to the Ereg locus. CRISPR deletion of Ereg in KPCE organoids normalized EGFR/mTORC1 activity.\",\n      \"method\": \"Autochthonous mouse model (KPCE), organoids, RNA-seq, ChIP, CRISPR/Cas9 deletion, Western blot, allograft models\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo autochthonous model, organoids, ChIP confirming direct binding, CRISPR epistasis confirming pathway dependence, multiple orthogonal methods\",\n      \"pmids\": [\"37345534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ELF3 is an oncogenic transcription factor in ASCL1-positive neuroendocrine carcinoma (NEC), regulated by a super-enhancer. Combining CUT&Tag (H3K27ac) and ELF3 knockdown RNA-seq defined the ELF3 transcriptional network, including downstream targets AURKA, CDC25B, CLDN4, ITGB6, and YWHAB. ELF3 depletion leads to poor NEC cell viability.\",\n      \"method\": \"ATAC-seq, CUT&Tag (H3K27ac), ELF3 siRNA knockdown + RNA-seq, loss-of-function cell viability assay\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ATAC-seq, CUT&Tag, and KD-RNA-seq define transcriptional network, single lab with multiple epigenomic and transcriptomic methods\",\n      \"pmids\": [\"36840413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Retinoic acid signaling (RAR/RXR) and Elf3 upregulate Netrin-1 in disseminated pancreatic ductal adenocarcinoma tumor cells as part of a feedforward metastatic niche mechanism involving hepatic stellate cell activation and retinoic acid secretion.\",\n      \"method\": \"In vitro and in vivo metastasis models, gene expression analysis, pathway inhibition\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ELF3's direct mechanistic role (e.g., direct promoter binding to Netrin-1) not explicitly demonstrated in abstract; indirect pathway inference only\",\n      \"pmids\": [\"37922311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ELF3 directly binds to the SLC31A1 (copper transporter) promoter and transcriptionally activates it, as demonstrated by luciferase reporter assay and ChIP. ELF3 is upregulated in cisplatin-induced acute kidney injury and positively correlates with SLC31A1 expression; ELF3-driven SLC31A1 induction increases copper uptake, causing mitochondrial dysfunction and cuproptosis.\",\n      \"method\": \"Luciferase reporter assay, ChIP, siRNA knockdown, Western blot, in vivo mouse AKI model\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct promoter binding by ChIP and reporter assay, functional knockdown with in vivo model, single lab\",\n      \"pmids\": [\"38462020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"WTAP-mediated N6-methyladenosine (m6A) modification of ELF3 mRNA promotes ELF3 expression in an m6A-dependent manner in human dermal fibroblasts. ELF3 overexpression induces cellular senescence; ELF3 directly binds the IRF8 promoter at the -817 to -804 site to induce IRF8-mediated SASP (senescence-associated secretory phenotype). shWTAP suppresses fibroblast senescence, which is reversed by exogenous ELF3 overexpression.\",\n      \"method\": \"Proteomics, m6A sequencing, ChIP (ELF3 binding to IRF8 promoter), siRNA/shRNA, overexpression, in vivo skin aging model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP confirming direct ELF3-IRF8 promoter binding, m6A mechanism, rescue experiments; single lab\",\n      \"pmids\": [\"38481803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ESE-1 (ELF3) upregulates GP73 expression in hepatocellular carcinoma cells by directly binding to the GP73 promoter, as demonstrated by ChIP. Both ESE-1 and GP73 are co-induced by IL-1β in vitro and in liver inflammation in vivo.\",\n      \"method\": \"ChIP, overexpression, siRNA knockdown, qRT-PCR, in vivo liver inflammation model\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding by ChIP, functional overexpression/KD, single lab\",\n      \"pmids\": [\"25530841\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ELF3 (also known as ESE-1, ERT, ESX) is an epithelium-specific ETS transcription factor that contains an ETS DNA-binding domain and an A/T hook domain; it functions primarily as a sequence-specific transcriptional activator or repressor of target gene promoters (including TGF-β RII, SPRR2A, Ang-1, COX-2, COL2A1, IGF1, EREG, SLC31A1, HLA-C, and miR-141-3p), is induced in non-epithelial cells by pro-inflammatory cytokines (IL-1β, TNF-α, IL-17A) via NF-κB and IκBζ, physically interacts with the androgen receptor to inhibit its recruitment to target gene promoters, and—uniquely—can act in the cytoplasm via its SAR domain to transform mammary epithelial cells through a non-transcriptional mechanism; its activity and localization are regulated by nuclear export signals (CRM1-dependent NES in the pointed domain and DNA-binding domain), m6A mRNA modification (by WTAP), and upstream kinase signaling through a RIPK4→IRF6→GRHL3→ELF3 hierarchy in keratinocytes, with ELF3 also creating an autoregulatory positive feedback loop at its own superenhancer-regulated promoter in trophoblasts.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ELF3 (ESE-1/ERT) is an epithelium-specific ETS-family transcription factor that programs epithelial differentiation and links pro-inflammatory signaling to target-gene control through sequence-specific binding at ETS sites [#0, #1]. Its bipartite DNA-binding architecture combines an ETS domain with an A/T-hook, with the transactivation function residing in the amino terminus [#0, #1]. As a context-dependent regulator it activates differentiation and signaling genes\\u2014SPRR2A and keratin K12 in keratinocyte/corneal differentiation, the TGF-\\u03b2 type II receptor to restore TGF-\\u03b2 growth suppression, and angiopoietin-1 and COX-2 in inflammation\\u2014while acting as a direct repressor of others such as COL2A1, MMP-9, and the miR-141/miR-144 microRNAs that gate ZEB1-driven EMT [#0, #1, #3, #4, #9, #10, #12, #14, #20, #25]. ELF3 is itself an inflammatory effector: pro-inflammatory cytokines (IL-1\\u03b2, TNF-\\u03b1, IL-17A) induce its expression through NF-\\u03baB and the co-factor I\\u03baB\\u03b6, and Elf3-deficient mice show altered cytokine output and skewed dendritic-cell\\u2013driven T-cell differentiation [#6, #11, #16, #28]. A distinctive feature is compartment-dependent dual function: nuclear ELF3 acts transcriptionally and can drive apoptosis, whereas cytoplasmic ELF3 transforms mammary epithelial cells through its serine/aspartate-rich (SAR) domain by a non-transcriptional mechanism, with localization governed by an A/T-hook NLS and two CRM1-dependent nuclear export signals [#8, #17]. ELF3 also represses androgen receptor activity by physically interacting with AR and blocking its promoter recruitment [#18]. Upstream, ELF3 is positioned within a RIPK4\\u2192IRF6\\u2192GRHL3 keratinocyte cornification hierarchy and is controlled by super-enhancers, m6A modification (WTAP), and autoregulatory feedback at its own promoter [#19, #23, #33]. Across cancers ELF3 has both tumor-suppressive (TGF-\\u03b2 RII restoration, EREG/EGFR-mTORC1 repression) and oncogenic (LUAD amplification, ASCL1+ neuroendocrine super-enhancer network, hypoxic IGF1/VEGF angiogenesis) roles depending on tissue context [#3, #22, #26, #29, #30].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established the founding identity of ELF3 as an epithelium-restricted ETS transcription factor with a unique two-domain DNA-binding architecture, answering what kind of regulatory protein it is.\",\n      \"evidence\": \"Molecular cloning, EMSA, and reporter assays on the SPRR2A promoter and Endo A enhancer\",\n      \"pmids\": [\"9234700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct in vivo target repertoire not yet defined\", \"Role of the A/T-hook versus ETS domain in target selection not dissected\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified TGF-\\u03b2 type II receptor as a direct ELF3 target and mapped functional domains, connecting ELF3 to growth-suppressive signaling.\",\n      \"evidence\": \"Yeast one-hybrid, EMSA, reporter assays, and deletion mapping on the TGF-\\u03b2 RII promoter\",\n      \"pmids\": [\"9417054\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of TGF-\\u03b2 RII activation not tested in this study\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated that ELF3 restores TGF-\\u03b2 growth-inhibitory signaling and reduces tumorigenicity, establishing a tumor-suppressive axis in breast cancer.\",\n      \"evidence\": \"Retroviral overexpression, Northern blot, and xenograft assays in Hs578t cells\",\n      \"pmids\": [\"10644990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endogenous ELF3 loss drives the tumor phenotype not addressed\", \"Mechanism of TGF-\\u03b2 RII silencing not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Linked ELF3 to epithelial differentiation programs beyond skin, showing it drives corneal keratin expression and is required for corneal epithelial differentiation.\",\n      \"evidence\": \"Reporter assays and antisense loss-of-function in corneal epithelial cells\",\n      \"pmids\": [\"11025204\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antisense specificity limited\", \"Direct binding to K12 element vs. indirect effect not separated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined how inflammation engages ELF3, showing IL-1\\u03b2 induces ELF3 via direct NF-\\u03baB binding to its promoter, casting ELF3 as a downstream inflammatory effector.\",\n      \"evidence\": \"Reporter mutants, EMSA supershift, adenoviral I\\u03baB, and ChIP in primary cells\",\n      \"pmids\": [\"12746898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream inflammatory targets not yet enumerated in this study\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed ELF3 operates within multi-factor differentiation complexes, cooperating with Skn-1a to drive SPRR2A.\",\n      \"evidence\": \"Co-transfection reporter assays and domain mapping\",\n      \"pmids\": [\"12624109\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physical interaction with Skn-1a not directly shown\", \"Cooperativity not validated at endogenous loci\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined ELF3 as a direct activator of pro-inflammatory/angiogenic genes (Ang-1, and later COX-2), expanding its inflammatory transcriptional program.\",\n      \"evidence\": \"Promoter mutagenesis, EMSA, transcriptional profiling, and dominant-negative assays\",\n      \"pmids\": [\"14715662\", \"15794755\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo requirement of ELF3 for Ang-1/COX-2 induction not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Revealed a compartment-specific dual mechanism: cytoplasmic ELF3 transforms via the SAR domain non-transcriptionally while nuclear ELF3 induces apoptosis transcriptionally.\",\n      \"evidence\": \"GFP localization, NLS/NES fusions, domain deletion, and transformation/apoptosis assays in mammary epithelial cells\",\n      \"pmids\": [\"15169914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoplasmic SAR-domain effector partners not identified\", \"Endogenous relevance of cytoplasmic pool not established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established ELF3 as a direct transcriptional repressor in addition to an activator, repressing COL2A1 and MMP-9 and extending the cytokine-driven NF-\\u03baB induction to airway epithelium.\",\n      \"evidence\": \"ChIP, EMSA, siRNA, reporter mapping, invasion/zymography assays, and Elf3 KO mice\",\n      \"pmids\": [\"18044710\", \"18302674\", \"18475289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of activator vs. repressor mode at a given promoter not defined\", \"Negative autoregulation mechanism partial\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected ELF3 to drug-induced apoptosis via EGR-1 and showed pharmacological control of its nuclear translocation.\",\n      \"evidence\": \"EMSA, ChIP, reporter, siRNA, and nuclear translocation assays in colorectal cancer cells\",\n      \"pmids\": [\"19074849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal coupling tolfenamic acid to ELF3 translocation not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapped the NLS/NES architecture controlling ELF3 localization and pinpointed NES2 as essential for SAR-domain transformation.\",\n      \"evidence\": \"GFP localization, site-directed mutagenesis of NLS/NES motifs, and transformation assays\",\n      \"pmids\": [\"21871131\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological signals regulating CRM1-dependent export not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined ELF3's organismal immune role, showing it controls dendritic-cell IL-12p40/IL-6 output and Th1/Th17 versus Th2 balance.\",\n      \"evidence\": \"Elf3 knockout mice, OVA airway models, ELISA, and flow cytometry\",\n      \"pmids\": [\"21948981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ELF3 binding at IL-12p40 not demonstrated\", \"Cell-intrinsic vs extrinsic contributions not fully separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Uncovered a non-ETS-DNA mechanism of action: ELF3 physically binds the androgen receptor and blocks its promoter recruitment, repressing AR signaling.\",\n      \"evidence\": \"Co-IP/pulldown, ChIP of AR recruitment, siRNA/overexpression, and xenografts in prostate cancer\",\n      \"pmids\": [\"23435425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction interface on ELF3/AR not mapped\", \"Whether other nuclear receptors are similarly inhibited unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed ELF3 within an upstream keratinocyte cornification signaling hierarchy (RIPK4\\u2192IRF6\\u2192GRHL3\\u2192ELF3).\",\n      \"evidence\": \"Sequential siRNA epistasis, qRT-PCR, and Western blot in keratinocytes\",\n      \"pmids\": [\"27667567\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect regulation of ELF3 by IRF6/GRHL3 not distinguished\", \"Single-lab epistasis\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined ELF3's role in EMT control by repressing ZEB1-activating microRNAs and antagonizing Wnt/RAS signaling, revealing context-dependent pro- and anti-EMT effects.\",\n      \"evidence\": \"ChIP at miR-141-3p promoter, RNA-seq, siRNA, and migration/invasion assays in liver and colorectal cancer\",\n      \"pmids\": [\"29523781\", \"30148686\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Opposing EMT directions across cancers not mechanistically reconciled\", \"Direct binding shown only in some contexts\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated ELF3 can act as an amplified oncogenic driver dependent on tissue context in lung adenocarcinoma.\",\n      \"evidence\": \"Genomic copy-number/methylation analysis and functional knockdown with tumor growth readout\",\n      \"pmids\": [\"31780666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Oncogenic transcriptional targets in LUAD not defined here\", \"Mechanism of subtype specificity unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed super-enhancer and autoregulatory control of ELF3 plus a MED-coactivator interaction required for HLA-C expression in trophoblasts.\",\n      \"evidence\": \"ChIP-PCR, siRNA, ATAC-seq, single-cell RNA-seq, and wrenchnolol disruption of ELF3-MED23\",\n      \"pmids\": [\"33622787\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of the autoregulatory loop beyond trophoblasts unknown\", \"MED23 vs MED1 contributions not fully separated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended ELF3 functions to hypoxic angiogenesis (IGF1/VEGF) and to vertebrate ECM/tissue morphogenesis.\",\n      \"evidence\": \"siRNA, ELISA, angiogenesis/xenograft assays in ovarian cancer; morpholino and CRISPR knockdown phenotyping in zebrafish\",\n      \"pmids\": [\"35695065\", \"36383615\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ELF3 binding to IGF1 promoter not fully confirmed\", \"ECM target genes downstream of Elf3 in zebrafish not directly bound\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Consolidated ELF3 as a bidirectional cancer regulator: tumor-suppressive via direct EREG repression limiting EGFR/mTORC1, and oncogenic via a super-enhancer-driven network in ASCL1+ neuroendocrine carcinoma.\",\n      \"evidence\": \"Autochthonous KPCE mouse model, organoids, ChIP, CRISPR epistasis (gallbladder); ATAC-seq, CUT&Tag, and KD-RNA-seq (neuroendocrine carcinoma)\",\n      \"pmids\": [\"37345534\", \"36840413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What dictates suppressor vs. oncogene behavior across lineages unresolved\", \"Cooperating factors in the NEC network not mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified post-transcriptional (m6A/WTAP) control of ELF3 and new direct targets driving fibroblast senescence (IRF8) and copper-dependent cell death (SLC31A1).\",\n      \"evidence\": \"m6A-seq, ChIP at IRF8 and SLC31A1 promoters, reporter assays, sh/siRNA, and in vivo aging/AKI models\",\n      \"pmids\": [\"38481803\", \"38462020\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reader/eraser logic of ELF3 m6A regulation incomplete\", \"Single-lab target validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved what molecular switch determines ELF3's opposing transcriptional outputs\\u2014activator vs. repressor at a given promoter, and tumor-suppressor vs. oncogene across tissues\\u2014and how its nuclear/cytoplasmic partitioning is dynamically controlled in vivo.\",\n      \"evidence\": \"No single study in the corpus reconciles the context-dependent dual functions\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model of cofactor-dependent activator/repressor switching\", \"Cytoplasmic SAR-domain effector pathway uncharacterized\", \"Genome-wide direct binding map across cell types absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 9, 10, 12, 18, 20, 23, 29, 32, 33]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 12, 23, 32, 33]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 13, 17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 9, 12, 23, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 11, 16, 28]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 4, 19, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 22, 26, 29, 30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"AR\", \"MED1\", \"MED23\", \"WTAP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}